Eight Drugs Added to Knowledgebase

This week we added eight new drugs to the knowledgebase:

• PN-943 is an alpha-4-beta-7-integrin antagonist for the treatment of ulcerative colitis is being developed by Protagonist Therapeutics
• CP101 a microbiome transplant for the prevention of recurrent Clostridium difficile infection (CDI) is being developed by Finch Therapeutics
• Lotilaner a mite GABA-Cl channel inhibitor for the treatment of Demodex blepharitis is being developed by Tarsus Pharmaceuticals
• Aroxybutynin/ atomoxetin a selective norepinephrine reuptake inhibitor & selective muscarinic inhibitor for the treatment of obstructive sleepa apnea is being developed by Apnimed
• Nomacopan a C5 and leukotriene B4 inhibitor for the treatment of chronic obstructive pulmonary disease (COPD), bullous pemphigoid and pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) is being developed by Akari Therapeutics
• Sovateltide an endothelin B receptor agonist for the treatment of acute ischemic stroke is being developed by Pharmazz
• Fazirsiran an antisense drug for the treatment of liver disease associated with alpha-1 antitrypsin deficiency is being developed by Arrowhead Pharmaceuticals and Takeda Pharmaceutical
• Fexapotide an apoptosis stimulant for the treatment of prostate cancer is being developed by Nymox

The Prescribe Right Pharmaceutical Pipeline Tracker now allows you to track 1,041 pipeline and recently approved drugs supported by 2,648 announced and published study results.